Advances in the Development of New Vaccines against Fasciola hepatica
Abstract Fasciolosis is a zoonosis caused by the trematode Fasciola hepatica that widely affects the livestock sector. However, an effective vaccine has not yet been developed to prevent the spread of this parasite. In this work, messenger ribonucleic acid technology has been used to develop a transcript of a recombinant protein of Fasciola hepatica that can be used to complete the formulation of a possible vaccine. Thanks to the use of plasmids as cloning vectors of the sequence of our antigenic protein of interest, in the study we will transform this protein into bacterial cultures for later transcription
- Referencias
- Cómo citar
- Del mismo autor
- Métricas
Beissert T, Perkovic M, Vogel A, Erbar S, Walzer K, Hempel T et al. A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity.Molecular Therap. 2020; 28: 119-128.
CDC-Centers for Disease Control and Diseases. Fascioliasis. DPDx - Laboratory Identification of Parasites of Public Health Concern. 2022 [última revisión 2 mayo 2019; citado 27 junio 2022]. Disponible en: https://www.cdc.gov/dpdx/fascioliasis/index.html
Deng Z, Tian Y, Song J, An G, Yang P. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Frontiers in Immunology. 2022; 13: 1-6
Howell A, Baylis M, Smith R, Pinchbeck G, Williams D. Epidemiology and impact of Fasciola hepatica exp,osure in high-yielding dairy herds. Preventive Veterinary Medicine. 2015; 121: 41-48.
Jackson N, Kester K, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines. 2020; 11: 1-5.
López-Abán J, Casanueva P, Nogal J, Arias M, Morrondo P, Diez-Baños P et al. Progress in the development of Fasciola hepatica vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD. Veterinary Parasitology. 2007; 145(3-4): 287-296.
Mas-Coma S, Valero M, Bargues M. Chapter 2 Fasciola, Lymnaeids and Human Fascioliasis, with a Global Overview on Disease Transmission, Epidemiology, Evolutionary Genetics, Molecular Epidemiology and Control. Advances in Parasitology. 2009; 69: 41-146.
Muro A, Ramajo V, López J, Simón F, Hillyer G. Fasciola hepatica: Vaccination of rabbits with native and recombinant antigens related to fatty acid binding proteins. Veterinary. 1997; 69(3-4): 219-229
Rodríguez-Pérez J, Rodríguez-Medina J, García-Blanco M, Hillyer G. Fasciola hepatica: Molecular cloning, nucleotide sequence, and expression of a gene encoding a polypeptide homologous to a Schistosoma mansoni fatty acid-binding protein. Experimental Parasitology. 1992; 74(4): 400-407.
Rong M, He B, McAllister W, Durbin R. Promoter specificity determinants of T7 RNA polymerase. Proceedings of the National Academy of Sciences. 1998; 95 (2): 515-519.
Trepotec Z, Geiger J, Plank C, Aneja M, Rudolph C. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA. 2019; 25(4): 507-518.
Zhang Q, Honko A, Zhou J, Gong H, Downs S, Vasquez J et al. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. Nano Letters. 2020; 20 (7): 5570-5574.
CDC-Centers for Disease Control and Diseases. Fascioliasis. DPDx - Laboratory Identification of Parasites of Public Health Concern. 2022 [última revisión 2 mayo 2019; citado 27 junio 2022]. Disponible en: https://www.cdc.gov/dpdx/fascioliasis/index.html
Deng Z, Tian Y, Song J, An G, Yang P. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Frontiers in Immunology. 2022; 13: 1-6
Howell A, Baylis M, Smith R, Pinchbeck G, Williams D. Epidemiology and impact of Fasciola hepatica exp,osure in high-yielding dairy herds. Preventive Veterinary Medicine. 2015; 121: 41-48.
Jackson N, Kester K, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines. 2020; 11: 1-5.
López-Abán J, Casanueva P, Nogal J, Arias M, Morrondo P, Diez-Baños P et al. Progress in the development of Fasciola hepatica vaccine using recombinant fatty acid binding protein with the adjuvant adaptation system ADAD. Veterinary Parasitology. 2007; 145(3-4): 287-296.
Mas-Coma S, Valero M, Bargues M. Chapter 2 Fasciola, Lymnaeids and Human Fascioliasis, with a Global Overview on Disease Transmission, Epidemiology, Evolutionary Genetics, Molecular Epidemiology and Control. Advances in Parasitology. 2009; 69: 41-146.
Muro A, Ramajo V, López J, Simón F, Hillyer G. Fasciola hepatica: Vaccination of rabbits with native and recombinant antigens related to fatty acid binding proteins. Veterinary. 1997; 69(3-4): 219-229
Rodríguez-Pérez J, Rodríguez-Medina J, García-Blanco M, Hillyer G. Fasciola hepatica: Molecular cloning, nucleotide sequence, and expression of a gene encoding a polypeptide homologous to a Schistosoma mansoni fatty acid-binding protein. Experimental Parasitology. 1992; 74(4): 400-407.
Rong M, He B, McAllister W, Durbin R. Promoter specificity determinants of T7 RNA polymerase. Proceedings of the National Academy of Sciences. 1998; 95 (2): 515-519.
Trepotec Z, Geiger J, Plank C, Aneja M, Rudolph C. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA. 2019; 25(4): 507-518.
Zhang Q, Honko A, Zhou J, Gong H, Downs S, Vasquez J et al. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity. Nano Letters. 2020; 20 (7): 5570-5574.
Perallón Mantas, D., Sánchez Montejo, J., & Muro Álvarez, A. (2023). Advances in the Development of New Vaccines against Fasciola hepatica. FarmaJournal, 8(1), 49–57. https://doi.org/10.14201/fj2023814957
Downloads
Download data is not yet available.
+
−